2025-11-14T17:23:30-05:00 2024-12-31 264150644 ESCALON 2345 YALE1ST ST FL PALO ALTO CA 94306 990 2024-01-01 911608978 ACCESS TO ADVANCED HEALTH INSTITUTE ACCE 2063810883 222 5TH AVE N SEATTLE WA 98109 JERRY KUO CFOO, V.P. & TREASUR 2063810883 2025-11-15 false ESTHER CHANG AN P01785250 4152343437 2025-11-14 2024 2025-03-06 01:10:19Z X JERRY KUO 5540 CANFIELD PLACE NORTH SEATTLE WA 98103 18401417 false X WWW.AAHI.ORG X 1993 WA DEVELOP VACCINES, ADJUVANTS, DIAGNOSTICS & DRUGS TO PREVENT, DETECT & TREAT INFECTIOUS DISEASES. 7 5 90 6 0 11574469 12565690 10631521 4362466 345516 308265 224869 1164996 22776375 18401417 0 0 11489626 11280651 0 0 12326239 24446905 23815865 35727556 -1039490 -17326139 39831178 20423547 14794761 12708130 25036417 7715417 X AAHI IS A NONPROFIT BIOTECH RESEARCH INSTITUTE, BRINGING TOGETHER THE BEST EXPERTS, TECHNOLOGIES, AND PLATFORMS TO CREATE ACCESSIBLE, HIGH-QUALITY PRODUCTS AND SOLUTIONS FOR HARNESSING THE IMMUNE SYSTEM TO ALLEVIATE DISEASE. false false FORMULATIONS - ADJUVANTS ARE POWERFUL IMMUNE-STIMULATING MOLECULES THAT INCREASE THE EFFICACY OF VACCINES AND ENHANCE THE IMMUNE SYSTEM'S ABILITY TO DESTROY TUMORS. AAHI HAS AMONG THE LARGEST PORTFOLIOS OF ADJUVANTS; IMPORTANTLY, AAHI SCIENTISTS FORMULATE THESE MOLECULES IN A WAY THAT MAKES THEM MINIMALLY TOXIC AND MAXIMALLY POTENT. IN PARTNERSHIP WITH VACCINE DEVELOPERS ACROSS THE WORLD, MANY AAHI ADJUVANT FORMULATIONS HAVE BEEN SAFELY ADMINISTERED TO THOUSANDS OF PEOPLE IN RIGOROUS CLINICAL TRIALS. AAHI'S ADJUVANT FORMULATIONS NOW ARE IN LEADING VACCINE CANDIDATES AGAINST HIV, TUBERCULOSIS, MALARIA, AND A MYRIAD OF OTHER INFECTIOUS DISEASES. MANUFACTURING AND CLINICAL SUPPORT - AAHI'S IN-HOUSE MANUFACTURING CAPABILITIES SUPPORT RAPID SCALE-UP AND PRODUCTION OF VACCINES FOR USE IN PHASE 1 AND PHASE 2 CLINICAL TRIALS AND COMPLETE AAHIS'S UNIQUE VACCINE DISCOVERY-DEVELOPMENT PROCESS. AAHI'S RESEARCH SCIENTISTS AND FORMULATIONS/PROCESS DEVELOPMENT TEAMS WORK WITH AAHI'S MANUFACTURING EXPERTS TO DEVELOP MANUFACTURING PROCESSES TO PRODUCE VACCINE CANDIDATES UNDER CONTROLLED CONDITIONS SO THAT THEY ARE SUITABLE FOR USE IN HUMAN STUDIES. THIS ENABLES AAHI TO QUICKLY AND EFFICIENTLY MOVE A VACCINE FROM LATE-STAGE RESEARCH TO EARLY PHASE CLINICAL STUDIES. AAHI CONSULTS LATER STAGE CLINICAL STUDIES. AAHI'S MANUFACTURING SUITE FOLLOWS US FDA "GOOD MANUFACTURING PRACTICE" REGULATIONS AND IS AN INVALUABLE RESOURCE TO AAHI SCIENTISTS. RNA VACCINES - RNA VACCINES HAVE BEEN SHOWN TO BE CRITICAL TOOLS FOR COMBATTING PANDEMICS AND HAVE BEEN SAFELY ADMINISTERED TO BILLIONS OF PEOPLE ACROSS THE GLOBE. AAHI'S RNA VACCINE PLATFORM IS DISTINCT FROM EXISTING LICENSED RNA VACCINES IN THAT IT IS BASED ON A SELF-AMPLIFYING RNA TECHNOLOGY AND DELIVERED BY A FLEXIBLE NANOSTRUCTURED LIPID CARRIER. TOGETHER, THESE FEATURES MEAN THAT THE VACCINE COULD BE STOCKPILED FOR YEARS, DELIVERED AT ROOM TEMPERATURE, AND MORE RAPIDLY MANUFACTURED TO ADDRESS FUTURE PANDEMICS. AAHI SCIENTISTS ARE ADVANCING RNA VACCINES AGAINST COVID-19, INFLUENZA, YELLOW FEVER, ZIKA, CHIKUNGUNYA, AND HIV, AND ADAPTING THE PLATFORM TO BE DELIVERED BY NASAL SPRAY OR DIRECTLY ADMINISTERED INTO TUMORS. 12812553 PROCESS AND PRODUCT DEVELOPMENT - MODERN VACCINES ARE INCREASINGLY COMPLEX AND THEIR DESIGN NEEDS TO BE TAILORED TO SPECIFIC TARGET PRODUCT PROFILES TO ENSURE PRACTICAL ACCESSIBILITY. SUSTAINABLE SOURCING OF RAW MATERIALS, STREAMLINED MANUFACTURING METHODS, AND TEMPERATURE STABILITY ARE CRITICALLY IMPORTANT TO ENABLE VACCINES FOR GLOBAL HEALTH APPLICATIONS IN RESOURCE-LIMITED SETTINGS. ALTERNATIVE ROUTES OF ADMINISTRATION, SUCH AS INTRANASAL DELIVERY, NOT ONLY MAY BEST BE SUITED TO FIGHT RESPIRATORY PATHOGENS BUT ALSO HELP TO ADDRESS VACCINE HESITANCY AND TO INCREASE VACCINE UPTAKE. AAHI SCIENTISTS ARE WORLD-EXPERTS AT DEVELOPING PROCESSES AND METHODS TO ADVANCE NOVEL PRODUCTS THAT MEET THE NEEDS OF VACCINE DEVELOPERS BOTH WITHIN AAHI AND EXTERNALLY AMONG THE DOZENS OF ACADEMIC, NON-PROFIT, AND COMMERCIAL PARTNERS. 12812553 12812553 true true false false false false false false false false true false false true true false true false false false true false false false false false false false false true false false false false false false false true false false false false true false false false false true 29 0 false 90 true false false false false false false false false X 7 5 true false false false false false false true true false false false false false false false false false SUZAN SNODGRASS 2063810883 5928 39TH AVE SW SEATTLE WA 98136 CANDICE DECAIRE CHIEF STRATE 40.00 X 634562 0 0 COREY CASPER CEO, PRESIDE 40.00 X X 516143 0 0 JERRY KUO CFOO, V.P. & 40.00 X 396150 0 0 ANNA MARIE BECKMANN EVP, PRODUCT 40.00 X 299448 0 0 CHRISTOPHER FOX SENIOR VP OF 32.00 X 263666 0 0 LINDA HAWKINS SENIOR DR. Q 40.00 X 246193 0 0 ROBRICK SMITH DIRECTOR, IN 40.00 X 215046 0 0 SUZAN SNODGRASS DIR. FINANCE 40.00 X 200054 0 0 ANDREW JOHNSON ASS. DIRECTO 40.00 X 196251 0 0 DARREN KLEMKOW DR. FACILITI 40.00 X 184366 0 0 EMILY VOIGT DR. RNA PROG 40.00 X 178112 0 0 LISA MCNEILL DR. MANUFACT 36.00 X 175014 0 0 ZACHARY SAGAWA DR. CLINICAL 40.00 X 173128 0 0 LISA BOUCHARD DR. QUALITY 40.00 X 170166 0 0 JEFFERY GUDERIAN DR. LABORATO 40.00 X 166204 0 0 DAMON PANG SENIOR CORPO 40.00 X 148533 0 0 RAOUL CONCEPCION BOARD MEMBER 0.50 X 54849 0 0 KEELEY FOLEY CHIEF EXICUT 40.00 X 10461 0 0 EDWARD HSU BOARD MEMBER 0.50 X 760 0 0 ROBERT APPELBAUM DIRECTOR 40.00 X 0 0 0 LINDA GAIL BEKKER DIRECTOR 40.00 X 0 0 0 CARLOS CORDON - CARDO DIRECTOR 40.00 X 0 0 0 GLENDA GRAY BORAD MEMBER 0.50 X 0 0 0 HARNIK GULATI DIRECTOR PJT 40.00 X 0 0 0 DAVID KERR BOARD MEMBER 0.50 X 0 0 0 ERIK LAURSEN DIRECTOR OF 40.00 X 0 0 0 EDWARD MOCARSKI BOARD MEMBER 0.50 X 0 0 0 PATRIC SOON-SHIONG BOARD CHAIR 0.50 X X 0 0 0 NEIL O'CONNER CFO & COO 40.00 X 0 0 0 4229106 16 false true false UNIVERSITY OF CALIFORNIA PO BOX 741816 LOS ANGELES CA 90074 SUB-CONTRACTORS 320902 COLORADO STATE UNIVERSITY FORT COLLINS FORT COLLINS CO 80523 SUB-CONTRACTORS 256087 REINHARD VEHRING 25 WILLOW STREET READING MA 01867 CONSULTING 225108 EMORY UNIVERSITY 1599 CLIFTON ROAD NE 4TH FLOOR ATLANTA GA 30322 SUB-CONTRACTORS 188631 UTMB AT GALVESTON OSP DEPT 750 PO BOX 660120 DALLAS TX 75266 SUB-CONTRACTORS 141042 5 12565690 12565690 LICENSING 1618950 1618950 REVENUE GMP PRODUCTS 989937 989937 NON FEDERAL CONTRACTS 927900 927900 CONSULTING & SERVICES REVENUE 493051 493051 REVENUE R&D MATERIALS 330607 330607 2021 2021 4362466 308265 308265 105866 105866 RENTAL INCOME 631069 631069 OTHER REVENUE 430215 430215 REALIZED GAIN/LOSS 300 300 -2454 -2454 1059130 18401417 5835727 10529816 5950727 4579089 33585 33585 717250 717250 4877755 1786343 3091412 298 298 78578 12719 65859 50351 340 50011 1486225 599002 887223 1116567 1116567 BAD DEBTS EXPENSES 8504574 108 8504466 RENT 2656835 2656835 LOSS ON ABANDONMENT OF 1198217 1198217 LAB SUPPLIES 1077543 1077543 3399962 3385771 14191 35727556 12812553 22915003 0 6910935 3388317 7634175 8000000 3252663 5931507 23493 554982 719340 649750 638083 22292310 17908713 5881470 4383597 1025031 959957 5922172 4379253 39831178 20423547 2740093 2271356 1311721 1283796 10742947 9152978 14794761 12708130 X 17036417 -284583 8000000 8000000 25036417 7715417 39831178 20423547 X -17326139 5139 X X false false true false X 3584439 6701932 33420108 11574469 12565690 67846638 3584439 6701932 33420108 11574469 12565690 67846638 67846638 532 622450 833118 1131815 308265 2896180 12382 15171 12291 39844 193881 5587477 121629 7940 5910927 76693589 5835727 0.88460 0.55050 X PART II, LINE 10 5,910,927 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 11377971 8922923 2455048 10914339 8985790 1928549 4383597 4379253 4379253 9152978 9152978 18401417 18401417 18401417 35727556 35727556 35727556 false BHARAT BIOTECH INTERNATIONAL LTD. N/A N/A 5400 CELLERON THERAPEUTICS LTD N/A N/A 28000 EUROPEAN VACCINE INITIATIVE N/A N/A 4083 EVAXION BIOTECH APS N/A N/A 1800 JANSSEN VACCINES & PREVENTION B.V. N/A N/A 259462 PATTERN PHARMA INC N/A N/A 1500 QURATIS, INC N/A N/A 1141450 SK BIOSCIENCE N/A N/A 76778 THE SOUTH AFRICAN MEDICAL RESEARCH COUNC N/A N/A 67700 UKGOF N/A N/A 4 UKOGF FOUNDATION N/A N/A 7 UNIVERSITY OF ALBERTA-C N/A N/A 2400 UNIVERSITY OF VICTORIA N/A N/A 3000 VALNEVA AUSTRIA GMBH N/A N/A 163500 1755084 1755084 false false false false false false SCHEDULE F, PAGE 1, PART I, LINE 3 BHARAT BIOTECH INTERNATIONAL LTD. 5,400 0 CELLERON THERAPEUTICS LTD 28,000 0 EUROPEAN VACCINE INITIATIVE 4,083 0 EVAXION BIOTECH APS 1,800 0 JANSSEN VACCINES & PREVENTION B.V. 259,462 0 PATTERN PHARMA INC 1,500 0 QURATIS, INC 1,141,450 0 SK BIOSCIENCE 76,778 0 THE SOUTH AFRICAN MEDICAL RESEARCH COUNC 67,700 0 UKGOF 4 0 UKOGF FOUNDATION 7 0 UNIVERSITY OF ALBERTA-C 2,400 0 UNIVERSITY OF VICTORIA 3,000 0 VALNEVA AUSTRIA GMBH 163,500 0 false false false false false false false false false CANDICE DECAIRE CHIEF STRATEGY OFFIC 634562 634562 COREY CASPER CEO, PRESIDENT 516143 516143 JERRY KUO CFOO, V.P. & TREASUR 396150 396150 ANNA MARIE BECKMANN EVP, PRODUCT DEVLOPM 299448 299448 CHRISTOPHER FOX SENIOR VP OF FORMULA 263666 263666 LINDA HAWKINS SENIOR DR. QUALITY 246193 246193 ROBRICK SMITH DIRECTOR, INFOR. TEC 215046 215046 SUZAN SNODGRASS DIR. FINANCE 200054 200054 ANDREW JOHNSON ASS. DIRECTOR PRO. M 196251 196251 DARREN KLEMKOW DR. FACILITIES & PRO 184366 184366 EMILY VOIGT DR. RNA PROGRAMME 178112 178112 LISA MCNEILL DR. MANUFACTURING 175014 175014 ZACHARY SAGAWA DR. CLINICAL RESEARC 173128 173128 LISA BOUCHARD DR. QUALITY CONTROL 170166 170166 JEFFERY GUDERIAN DR. LABORATORY MANAG 166204 166204 IMMUNITY BIO BOARD MEMBER 10000 ANNUAL LICE false SCHEDULE L, PART V SCH L, PART IV, BUSINESS TRANSACTIONS INVOLVING INTERESTED PERSONS: (A) NAME OF PERSON: IMMUNITY BIO (B) RELATIONSHIP BETWEEN INTERESTED PERSON AND ORGANIZATION: BOARD MEMBER >35% OWNER OF THE ORGANIZATION (C) AMOUNT OF TRANSACTION 6,574,703. (D) DESCRIPTION OF TRANSACTION: ANNUAL LICENSING AGREEMENT, CONTRACT SERVICES, PRODUCT & MATERIALS PROCEEDS (E) SHARING OF ORGANIZATION REVENUES? = NO FORM 990 - ORGANIZATION'S MISSION AAHI IS A NONPROFIT BIOTECH RESEARCH INSTITUTE, BRINGING TOGETHER THE BEST EXPERTS, TECHNOLOGIES, AND PLATFORMS TO CREATE ACCESSIBLE, HIGH-QUALITY PRODUCTS AND SOLUTIONS FOR HARNESSING THE IMMUNE SYSTEM TO ALLEVIATE DISEASE. FORM 990, PAGE 2, PART III, LINE 4B MANUFACTURING AND CLINICAL SUPPORT - AAHI'S IN-HOUSE MANUFACTURING CAPABILITIES SUPPORT RAPID SCALE-UP AND PRODUCTION OF VACCINES FOR USE IN PHASE 1 AND PHASE 2 CLINICAL TRIALS AND COMPLETE AAHIS'S UNIQUE VACCINE DISCOVERY-DEVELOPMENT PROCESS. AAHI'S RESEARCH SCIENTISTS AND FORMULATIONS/PROCESS DEVELOPMENT TEAMS WORK WITH AAHI'S MANUFACTURING EXPERTS TO DEVELOP MANUFACTURING PROCESSES TO PRODUCE VACCINE CANDIDATES UNDER CONTROLLED CONDITIONS SO THAT THEY ARE SUITABLE FOR USE IN HUMAN STUDIES. THIS ENABLES AAHI TO QUICKLY AND EFFICIENTLY MOVE A VACCINE FROM LATE-STAGE RESEARCH TO EARLY PHASE CLINICAL STUDIES. AAHI CONSULTS LATER STAGE CLINICAL STUDIES. AAHI'S MANUFACTURING SUITE FOLLOWS US FDA "GOOD MANUFACTURING PRACTICE" REGULATIONS AND IS AN INVALUABLE RESOURCE TO AAHI SCIENTISTS. FORM 990, PAGE 2, PART III, LINE 4D PROCESS AND PRODUCT DEVELOPMENT - MODERN VACCINES ARE INCREASINGLY COMPLEX AND THEIR DESIGN NEEDS TO BE TAILORED TO SPECIFIC TARGET PRODUCT PROFILES TO ENSURE PRACTICAL ACCESSIBILITY. SUSTAINABLE SOURCING OF RAW MATERIALS, STREAMLINED MANUFACTURING METHODS, AND TEMPERATURE STABILITY ARE CRITICALLY IMPORTANT TO ENABLE VACCINES FOR GLOBAL HEALTH APPLICATIONS IN RESOURCE-LIMITED SETTINGS. ALTERNATIVE ROUTES OF ADMINISTRATION, SUCH AS INTRANASAL DELIVERY, NOT ONLY MAY BEST BE SUITED TO FIGHT RESPIRATORY PATHOGENS BUT ALSO HELP TO ADDRESS VACCINE HESITANCY AND TO INCREASE VACCINE UPTAKE. AAHI SCIENTISTS ARE WORLD-EXPERTS AT DEVELOPING PROCESSES AND METHODS TO ADVANCE NOVEL PRODUCTS THAT MEET THE NEEDS OF VACCINE DEVELOPERS BOTH WITHIN AAHI AND EXTERNALLY AMONG THE DOZENS OF ACADEMIC, NON-PROFIT, AND COMMERCIAL PARTNERS. FORM 990, PAGE 6, PART VI, LINE 2 IMMUNITY BIO IMMUNITY BIO BOARD MEMBER BOARD MEMBER BOARD MEMBER FORM 990, PAGE 6, PART VI, LINE 11B NO REVIEW WAS OR WILL BE CONDUCTED. FORM 990, PAGE 6, PART VI, LINE 19 NO DOCUMENTS AVAILABLE TO THE PUBLIC FORM 990, PART XI, LINE 9 OTHER INCREASE 5,139 FORM 990, PAGE 12, PART XII, LINE 3B NO TIGER DEVELOPMENT LLC 3800 N CENTRAL AVE 460 PHOENIX AZ 85010 PATENT HOL AZ ACCESS TO ACCESS TO ADVANCED HEALTH INSTITUE